Supernus Pharmaceuticals, Inc. (SUPN)
| Market Cap | 1.46B |
| Revenue (ttm) | 601.35M |
| Net Income (ttm) | 73.35M |
| Shares Out | 53.41M |
| EPS (ttm) | 1.31 |
| PE Ratio | 20.75 |
| Forward PE | 20.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 298,779 |
| Open | 26.89 |
| Previous Close | 26.98 |
| Day's Range | 26.36 - 27.36 |
| 52-Week Range | 23.15 - 34.50 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 36.21 (+32.8%) |
| Earnings Date | May 9, 2022 |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The ...
Financial Performance
In 2021, SUPN's revenue was $579.78 million, an increase of 11.41% compared to the previous year's $520.40 million. Earnings were $53.42 million, a decrease of -57.92%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 36.21, which is an increase of 32.78% from the latest price.
News
Supernus Announces First Quarter 2022 Financial Results
ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...
FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients
The FDA approved an expanded indication for Supernus Pharmaceuticals Inc's (NASDAQ: SUPN) Qelbree (viloxazine extended-release capsules) for attention deficit hyperactivity disorder (ADHD) in adult pati...
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md. , May 2, 2022 /PRNewswire/ -- Supernus Pharmaceuticals, Inc. (Nas...
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
ROCKVILLE, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus to Participate in Annual Cowen Health Care Conference
ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
ROCKVILLE, Md., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Febru...
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
Supernus (SUPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Supernus (SUPN)
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
Supernus Pharmaceuticals Targeted in Ransomware Incident
The attack had no significant impact on the business and did not cause any significant disruption to Company's operations
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender O...
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of...
Supernus to Participate in Upcoming November Investor Conferences
ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Beat Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 90.48% and 5.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals: Q3 Earnings Insights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Supernus Announces Third Quarter 2021 Financial Results
ROCKVILLE, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
Why Supernus' Acquisition of Adamas Is a Smart Move
Adamas looks like a good fit for Supernus.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Adamas Pharmaceuticals, Inc.
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. ("Adamas" ...
Supernus Pharmaceuticals to acquire this Pharmaceuticals company for $400 million
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals (NASDAQ: ADMS). Supernus is to purchase this company a tender o...